FDA lifts partial hold on Xencor leukemia study

FDA lifts partial hold on Xencor leukemia study

The hold had been placed in February following two deaths in the study, including one in a patient who experienced cytokine release syndrome. The company has amended the trial protocol to mandate monitoring and management of CRS.

Source: http://bit.ly/2XQZcja